Comtan (entacapone), a new drug for advanced Parkinson's disease

December 1999

Novartis is now introducing Comtan (entacapone), a new drug for advanced Parkinson's disease.

It's given to enhance the effectiveness of levodopa/carbidopa (Sinemet, etc).

Comtan is a COMT inhibitor...in the same class as Tasmar (tolcapone). But Comtan isn't expected to have the same problems with liver toxicity.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter membership benefits include:

12 issues every year — what you need to know and do, right now
Quick, practical reference charts and tools
Comprehensive CE library to meet license renewal and state requirements
Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
Plus much more!

Choose the right tier for your needs today.

Already a subscriber? Log in

Volume pricing available. Get a quote